Glutathione Therapeutic Use

Studies both domestically and internationally have shown that the sustained response rate (ALT normalization, DNA seroconversion, and HBeAg seroconversion) of thymosin α1 alone in the treatment of chronic hepatitis B is approximately 37%, similar to that of interferon alone, but without the toxic side effects of interferon.

Clinical studies in Taiwan using thymosin α1 for the treatment of chronic hepatitis B have demonstrated a delayed therapeutic effect. After the end of thymosin α1 treatment, there is a transient increase in ALT, accompanied by HBeAg seroconversion and loss of HBV DNA.

The superiority of HBV DNA seroconversion and seroconversion suggests that thymosin α1 alone has long-term efficacy in the treatment of chronic hepatitis B without significant adverse effects. High-dose thymosin α1 is particularly effective in patients with advanced liver fibrosis.